Table 1.

Baseline characteristics of the study population.

	All subjects (n = 19)
Age (years)   Gender   – Male   – Female	10 (3)   12 (63)   7 (37)
Duration of IgG treatment (years)	3 (3)
Ethnic background   – Caucasian   – Asian   – Other	17 (90)   1 (5)   1 (5)
IgG treatment ever and current   – Intravenous and subcutaneous   – Intravenous   – Subcutaneous	9 (47)   5 (26)   5 (26)
IgG treatment location ever and current   – Hospital/ outpatient care unit   – Hospital/ at home   – At home	5 (26)   13 (68)   1 (5)
Type of immunodeficiency   – CVID   – CID   – APDS   – ARA   – Complement deficiency   – Specific antibody deficiency   – XLF/Cernunnos deficiency   – Other primary antibody deficiency	5 (26)   3 (16)   3 (16)   1 (5)   1 (5)   1 (5)   1 (5)   4 (21)

Values for mean (SD) or total number (percentage) are shown.

APDS: Activated PI3K delta syndrome; ARA: Autosomal recessive agammaglobulinaemia; CID: Combined immunodeficiency; CVID: Common variable immune deficiency; XLF: XRCC4-like factor.